Kromann Reumert advises KKR on minority equity stake investment in Nordic Bioscience
KKR will acquire a minority equity stake in Nordic Bioscience from existing shareholders and will support the company in accelerating its global growth.
Kromann Reumert has advised KKR on its purchase of a minority equity stake in Danish Nordic Bioscience from the existing shareholders.
Nordic Bioscience is a world-leader in biomarkers which are measurable indicators of biological change or response used for the development of diagnostic tools and identification of new drug candidates. Nordic Bioscience has established a position as the world’s most experienced company within the extracellular matrix (ECM) through more than 25 years of dedicated research and development. The ECM is the non-cellular component of all tissues and organs and can be analyzed to identify new drug candidates in more than 50 disease areas, diagnose patients and evaluate the effect of existing drugs and drug candidates.
KKR is making the investment through the firm’s Health Care Strategic Growth Fund, which is focused on investing in leading high-growth health care companies.
Kromann Reumert has advised KKR throughout the process highlighting and reinforcing our strong focus and expertise in the life science sector and showcasing our abilities in helping international investors investing into Danish assets.
For more, see the press release:
Nordic Bioscience Welcomes Investment from KKR for Next Phase of Growth
and the article in Børsen (in Danish):
Biotekrigmand sælger ud af livsværk: Kapitalfond får andel i Nordic Bioscience for 100 mio. dollar
Contact
